pyruvaldehyde has been researched along with Disease Exacerbation in 10 studies
Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.
methylglyoxal : A 2-oxo aldehyde derived from propanal.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robertson, DS | 1 |
| Iguchi, D | 1 |
| Mizuno, M | 1 |
| Suzuki, Y | 1 |
| Sakata, F | 1 |
| Maruyama, S | 1 |
| Okada, A | 1 |
| Okada, H | 1 |
| Ito, Y | 1 |
| Tezuka, Y | 1 |
| Nakaya, I | 1 |
| Nakayama, K | 1 |
| Nakayama, M | 1 |
| Yahata, M | 1 |
| Soma, J | 1 |
| Wetzels, S | 1 |
| Vanmierlo, T | 1 |
| Scheijen, JLJM | 1 |
| van Horssen, J | 1 |
| Amor, S | 1 |
| Somers, V | 1 |
| Schalkwijk, CG | 1 |
| Hendriks, JJA | 1 |
| Wouters, K | 1 |
| Zou, XY | 1 |
| Ding, D | 1 |
| Zhan, N | 1 |
| Liu, XM | 1 |
| Pan, C | 1 |
| Xia, YM | 1 |
| Genuth, S | 2 |
| Sun, W | 2 |
| Cleary, P | 1 |
| Gao, X | 2 |
| Sell, DR | 2 |
| Lachin, J | 1 |
| Monnier, VM | 2 |
| Zhu, D | 1 |
| Wang, L | 1 |
| Zhou, Q | 1 |
| Yan, S | 1 |
| Li, Z | 1 |
| Sheng, J | 1 |
| Zhang, W | 1 |
| Cleary, PA | 1 |
| Lachin, JM | 1 |
| Takahashi, K | 1 |
| Tatsunami, R | 1 |
| Tampo, Y | 1 |
| Han, Y | 1 |
| Randell, E | 1 |
| Vasdev, S | 1 |
| Gill, V | 1 |
| Gadag, V | 1 |
| Newhook, LA | 1 |
| Grant, M | 1 |
| Hagerty, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diabetes Control and Complications Trial (DCCT)[NCT00360815] | 1,441 participants | Interventional | 1983-08-31 | Completed | |||
| Epidemiology of Diabetes Interventions and Complications (EDIC)[NCT00360893] | 1,441 participants (Actual) | Observational | 1994-04-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pyruvaldehyde and Disease Exacerbation
| Article | Year |
|---|---|
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
Topics: Adult; Arginine; Asymptomatic Diseases; Biomarkers; Biopsy; Cardiovascular Diseases; Carotid Artery | 2015 |
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
Topics: Adult; Arginine; Asymptomatic Diseases; Biomarkers; Biopsy; Cardiovascular Diseases; Carotid Artery | 2015 |
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
Topics: Adult; Arginine; Asymptomatic Diseases; Biomarkers; Biopsy; Cardiovascular Diseases; Carotid Artery | 2015 |
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
Topics: Adult; Arginine; Asymptomatic Diseases; Biomarkers; Biopsy; Cardiovascular Diseases; Carotid Artery | 2015 |
9 other studies available for pyruvaldehyde and Disease Exacerbation
| Article | Year |
|---|---|
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rats pretreated with methylglyoxal.
Topics: Animals; Complement Activation; Complement C5a; Complement Inactivating Agents; Disease Models, Anim | 2018 |
Methylglyoxal as a prognostic factor in patients with chronic kidney disease.
Topics: Aged; Arginine; Biomarkers; Cardiovascular Diseases; Deoxyglucose; Diabetic Nephropathies; Disease P | 2019 |
Methylglyoxal-Derived Advanced Glycation Endproducts Accumulate in Multiple Sclerosis Lesions.
Topics: Aged; Astrocytes; Biomarkers; Disease Progression; Disease Susceptibility; Female; Glycation End Pro | 2019 |
Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Disease Progression; | 2015 |
Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopath | 2015 |
(+)-Catechin ameliorates diabetic nephropathy by trapping methylglyoxal in type 2 diabetic mice.
Topics: Animals; Catechin; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progr | 2014 |
[Methylglyoxal-induced apoptosis of endothelial cells].
Topics: Animals; Apoptosis; Caspase 3; Cattle; Cells, Cultured; Diabetes Complications; Diabetes Mellitus; D | 2008 |
Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with Type 1 diabetes.
Topics: Adolescent; Adult; Cell Membrane; Child; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Disease P | 2007 |